Stock search

Ticker or company name

Compare stocks

Market: US

  • CICigna
  • CORCencora
  • ELVElevance Health

Add stock

Ticker or company

Summary

CI
Cigna
$300,16Up +1,06%
Year: Up +10%
89/100Best scoreRatio would consider buying
Open stock page
COR
Cencora
$356,94Down −0,58%
Year: Down −4%
83/100Ratio would consider buying
Open stock page
ELV
Elevance Health
$446,28Up +3,86%
Year: Up +31%
78/100Ratio would consider buying
Open stock page

Verdict

CI has the best score (89). CI grows revenue the fastest. CI is the cheapest by forward P/E. ELV has the lowest debt load. ELV has the highest net margin.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckCI7 ✓ 2 — 0 ✕COR6 ✓ 3 — 0 ✕ELV6 ✓ 2 — 1 ✕
P/E vs its history13,119,718,1
P/E vs industry13,119,718,1
Forward P/E9,116,814,0
Revenue growth, YoY+6,8%+5,1%+3,6%
EPS growth, YoY+0,3%+38,3%−4,1%
Net margin2,3%0,8%2,5%
Net debt / EBITDA−0,62,4−0,8
Free cash flow$9,43 bn$4,06 bn$6,51 bn
Share count over a year−1,4%−0,7%−2,7%
Cash runwayn/anot neededn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterCITTMCORTTMELVTTMIndustry medianTTM
P/E TTM ↓Best: 13,1Worst: 19,718,125,1
Forward P/E ↓Best: 9,1Worst: 16,814,016,2
PEG ↓Best: 1,42,4Worst: 4,02,2
P/S TTM ↓0,3Best: 0,2Worst: 0,52,2
EV/EBITDA ↓Best: 8,9Worst: 15,113,817,3
P/FCF ↓Best: 8,710,9Worst: 13,819,5

Price, %

  • CIn/a
  • CORn/a
  • ELVn/a

Returns

Best WorstNo mark — in between

PeriodCICORELV
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

CICORELV
Share of “buy”Best: 74%70%Worst: 68%
Beat the forecastWorst: 1 of 43 of 4Best: 4 of 4
Average “surprise”+0,4%Worst: +0,1%Best: +22,1%
Insiders over 12 monthssales $66,8 msales $13,1 msales $4,74 m

Details are on each stock page.